UCB S.A. UNSP.ADR 1/2 Total Assets
UCB S.A. UNSP.ADR 1/2 total assets. Based on the latest financial reports, UCB S.A. UNSP.ADR 1/2 (UNC0) holds total assets worth €20.63 Billion EUR (≈ $24.12 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see UNC0 cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of UCB S.A. UNSP.ADR 1/2 (2021–2025)
Total assets of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025. This chart illustrates how UCB S.A. UNSP.ADR 1/2's total assets have evolved over time, based on quarterly financial data. See UCB S.A. UNSP.ADR 1/2 share price for real-time trading data and today's change.
UCB S.A. UNSP.ADR 1/2 - Asset Composition Analysis
UCB S.A. UNSP.ADR 1/2 Total Assets Breakdown (December 2025)
UCB S.A. UNSP.ADR 1/2 total assets breakdown as of December 2025. UCB S.A. UNSP.ADR 1/2's total assets of €20.63 Billion consist of 33.3% current assets and 66.7% non-current assets. Explore UNC0 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.4% |
| Accounts Receivable | €1.33 Billion | 7.3% |
| Inventory | €1.50 Billion | 8.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.45 Billion | 19.0% |
| Goodwill | €5.09 Billion | 28.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how UCB S.A. UNSP.ADR 1/2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: UCB S.A. UNSP.ADR 1/2's current assets represent 33.3% of total assets in 2025, an increase from 26.1% in 2021.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 8.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, a decrease from 58.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 28.0% of total assets.
UCB S.A. UNSP.ADR 1/2 Competitors by Total Assets
Key competitors of UCB S.A. UNSP.ADR 1/2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
UCB S.A. UNSP.ADR 1/2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 1.35 | 1.19 |
| Quick Ratio | 0.82 | 1.01 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €923.00 Million | €1.39 Billion | €522.00 Million |
UCB S.A. UNSP.ADR 1/2 - Advanced Valuation Insights
This section examines the relationship between UCB S.A. UNSP.ADR 1/2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.66 |
| Latest Market Cap to Assets Ratio | 2.47 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | €18.16 Billion |
| Market Capitalization | $44.84 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values UCB S.A. UNSP.ADR 1/2's assets at a significant premium (2.47x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: UCB S.A. UNSP.ADR 1/2's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for UCB S.A. UNSP.ADR 1/2 (2021–2025)
The table below shows the annual total assets of UCB S.A. UNSP.ADR 1/2 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €18.16 Billion ≈ $21.23 Billion |
+4.68% |
| 2024-12-31 | €17.35 Billion ≈ $20.28 Billion |
+11.64% |
| 2023-12-31 | €15.54 Billion ≈ $18.17 Billion |
-2.07% |
| 2022-12-31 | €15.87 Billion ≈ $18.55 Billion |
+11.67% |
| 2021-12-31 | €14.21 Billion ≈ $16.61 Billion |
-- |
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthr… Read more